Aims: Despite therapeutic advances in glioma management including surgery, radiation, and chemotherapy, the improvement of patient outcome is far from satisfactory.
| INTRODUCTION
Gliomas are the most prevalent primary tumors of the central nervous system (CNS) with certain glial cell-like characteristics. 1, 2 According to pathologic evaluation, gliomas are classified into four grades from Grade I to IV, depending on which the survival time of glioma patients varies strikingly. 3 For example, patients with pilocytic astrocytoma (Grade I) had a five-year survival rate of 94.4%, much higher than 4.7%, the five-year survival rate of patients with glioblastoma multiforme (GBM, Grade IV). 4 Despite therapeutic advances in surgery, radiation, and pharmacotherapy, the median survival for GBM patients is only 14 months. [5] [6] [7] With the identification of specific genetic mutations as "driver factors" of gliomagenesis, molecular parameters have been introduced to refine the diagnosis of gliomas such as IDH mutation, 1p/19q codeletion, and H3 K27M mutation, along with pathological parameters. 1, 8 However, current glioma management is unsatisfactory in terms of survival gain. Therefore, it is critical to investigate mechanisms underlying glioma initiation and malignant evolution and to dig out biomarkers with targetable potential for attenuating the lethality of glioma and improving patients' prognosis.
Nucleolar and spindle-associated protein 1 (NUSAP1) is involved in regulating the assembly of spindle and maintaining normal cytokinesis by virtue of its microtubule-binding and DNA-binding domains, which renders it an important regulator in mitosis and cell proliferation. [9] [10] [11] The cellular expression and distribution of NUSAP1 is under rigorous control. Dysregulation of NUSAP1 has been identified in different tumors including hepatocellular carcinoma, lung adenocarcinoma, and renal cell carcinoma. [12] [13] [14] NUSAP1 upregulation is associated with malignant progression of melanoma and oral squamous cell carcinoma. 15, 16 Moreover, NUSAP1 may confer resistance to DNA-damaging drugs due to its participation in DNA double-strand break repair. 17 However, the role of NUSAP1 in glioma development and its association with glioma grade remains unclear.
In this study, we evaluated the expression of NUSAP1 in gliomas with varying grades using microarray data, immunohistochemistry data, and performing reverse transcription-PCR (RT-PCR) analysis. The prognostic significance of NUSAP1 in gliomas was investigated. We also conducted in vitro loss of function experiments to explore the effects of NUSAP1 on phenotypes of glioma cells. Our data showed that NUSAP1 expression was associated not only with glioma grade but also with prognosis of glioma patients, and that NUSAP1 depletion would suppress proliferation of glioma cells by inducing cell cycle arrest and apoptosis.
| MATERIALS AND METHODS

| Transcriptome data
Three glioma microarray datasets GSE4290, GSE4412, and GSE43378
were downloaded from the GEO database. The Cancer Genome Atlas (TCGA) RNA-seq data of GBM and corresponding clinical data were downloaded from UCSC Cancer Browser (https://genome-cancer.
ucsc.edu/). Samples without complete clinical information were excluded. Table S1 . 18 Twenty-four hours or forty-eight hours after transfection, cells were subjected to either RNA extraction or further assays, or protein extraction, respectively.
| Patients and tissue specimens
| Real-Time RT-PCR
Total RNA of glioma cell lines or tissues was isolated with RNAiso Plus (Takara, China) and reverse-transcribed into cDNA by PrimeScript™ RT reagent Kit (Takara). The PCR amplification procedure using the LightCycler ® 480 Instrument (Roche, Switzerland) was described previously. 19 Briefly, 2 μL cDNA template was amplified in a 20-μL reaction mix system of SYBR (E) NUSAP1 protein expression in lowgrade and high-grade glioma. Images were taken from the human protein atlas (http://www.proteinatlas.org). *P < 0.05, **P < 0.01, ***P < 0.001
| Western blotting
Cells were lysed for protein extraction using PMSF-containing RIPA lysis solution (Beyotime, China). Protein extracts were electrophoresed on a 10% SDS-PAGE gel and transferred onto a nitrocellulose membrane.
The blotted membrane was then blocked in 5% skimmed milk and incubated with corresponding primary antibodies overnight at 4°C. The primary antibodies against NUSAP1 (Proteintech Group, USA) and GAPDH (Sigma-Aldrich, USA) were diluted and used following the manufactures'
recommendations. The protein bands were visualized via the ChemiDoc XRS+ image analyzer (Bio-Rad, USA) shortly after soaked with dilutions of the enhanced chemiluminescence reagent (GE Healthcare, UK). 
| MTS and colony-formation assays for cell proliferation
| Cell cycle analysis
U251 cells were harvested and fixed in precooled 70% ethanol for 12 h at 4°C. After fixation, cells were centrifuged at 1000 rpm for 5 min and resuspended in staining solution (500 μL staining buffer solution, 25 μL propidium iodide, and 10 μL ribonuclease A for each sample; Beyotime), followed by incubation for 30 min at 37°C in the dark. A total of 10 000 cells for each sample were acquired, and their DNA contents were 
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analyzed using Cytomics™ FC500 Flow Cytometer (Beckman Coulter, USA) under 488 nm excitation wavelength.
| Wound-healing assay
Cells transfected with siRNA were seeded into a 6-well plates at a density of 1 × 10 6 cells per well. After cells were grown to confluence, wounds were introduced by scraping the monolayer cells using 100-μL pipette tips. Prior to adding DMEM supplemented with 2% FBS, cells were washed with PBS to remove floating cells. The process of wound healing was monitored at indicated time points using a photographable microscope (Leica, German). The areas of scratches were quantified using ImageJ (Bethesda, USA).
| Cell apoptosis assay
Apoptotic cells were detected under a fluorescence microscope (Leica) using the Hoechst Staining Kit (Beyotime) according to the manufacture's instruction. In brief, cells were fixed overnight at 4°C and washed with PBS, followed by Hoechst 33258 staining for 5 min in the dark.
| Statistical analysis
Differences in experimental data between groups were evaluated using unpaired Student's t tests or one-way ANOVA. To compare overall survival times of patients in GSE4412 and GSE43378, the Kaplan-Meier method and the log-rank test were used. 20 The Cox proportional hazards regression model was used to assess the effects of clinical variables on patients' overall survival. All statistical analyses were performed by SPSS 22.0 or GraphPad Prism 5. Differences were considered statistically significant when P < 0.05.
| RESULTS
| NUSAP1 expression in different grades of glioma
To investigate the transcriptional level of NUSAP1 in glioma, we downloaded and analyzed three microarray datasets (GSE4290, GSE4412, and GSE43378) and the TCGA RNA-seq dataset of GBM, with a total of 487 samples included. Basic clinical features of each dataset were listed in Table 1 . As compared with normal brain tissues, NUSAP1 was consistently upregulated in glioma tissues in GSE4290 and TCGA datasets which contained normal specimens ( Figure 1A,B) . Furthermore, patients with distinct glioma grades had different NUSAP1 levels, showing a tendency that NUSAP1 expression was significantly increased with the malignant degree of glioma rising (Figure 2A-C) . To validate these different expressing patterns, we measured NUSAP1 mRNA levels by RT-PCR in another cohort consisted of 54 glioma samples, clinical information of which was listed in Table 2 . As shown in Figure 2D , the average level of NUSAP1 was higher in patients with high-grade glioma (Grade III and IV) than in those with low-grade glioma (Grade I and II; P = 0.019).
We next asked if the protein level of NUSAP1 exhibited a similar expression trend. To this end, we analyzed immunohistochemistry 
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F I G U R E 4 NUSAP1 silencing was achieved using specific siRNAs. These results consistently indicated that NUSAP1 expression was positively correlated with pathological grade of glioma.
| NUSAP1 expression is correlated with poor prognosis of glioma patients
Survival time data of patients in GSE4412 and GSE43378 enabled us to evaluate the prognostic significance of NUSAP1 in glioma patients, although we had not obtained survival data of all the 54 patients mentioned above. As shown in Figure 3A To rule out the possibility that the poorer prognosis of patients with high NUSAP1 expression was a result of higher pathological grades, we further performed multivariate Cox proportional hazards regression analyses, introducing other clinical variables. As shown in Table 3 , NUSAP1 level and WHO grade were independent prognosis factors. In addition, age and the Karnofsky performance score (KPS)
were also independent prediction factors for OS (Table 4 ).
| Knockdown of NUSAP1 suppresses proliferation and migration of glioma cells
To investigate the role of NUSAP1 in glioma progression, we performed in vitro assays evaluating phenotypic alterations of glioma cells after siRNA-induced NUSAP1 depletion. The interference efficacy of two different NUSAP1 siRNAs was evaluated at both the mRNA and protein levels. As shown in Figure 4A A decreased proliferation rate could be also due to increased cell death. For this reason, we next investigated the effects of NUSAP1 loss on apoptosis of U251 cells using Hoechst 33258 which enables us to distinguish apoptotic cells from nonapoptotic cells based on the staining intensity of cell nuclei. As shown in Figure 5D , the proportion of cells with densely stained nuclei was higher in NUSAP1-depleted cells than in control cells, which indicated that NUSAP1 ablation would induce apoptosis in glioma cells. Despite elevated apoptotic cells after NUSAP1 knock down, no significant alterations of caspase 3 and cleaved caspase 3 levels were observed according to the immunoblotting assay ( Figure S1 ). It is possible that NUSAP1 depletioninduced cell apoptosis is the result of involvement of other apoptosis proteins. Collectively, our investigations demonstrate that NUSAP1 is implicated in maintaining growth of glioma cells by regulating cell cycle progression and influencing the occurrence of cell apoptosis.
| NUSAP1 depletion renders glioma cells impaired migratory ability
High-grade gliomas are characterized by high invasiveness which is a challenge for complete surgical resection of tumors. To explore whether NUSAP1 was implicated in glioma migration, we next tested the migrating ability of NUSAP1-depleted U251 cells by calculating the ratios of the residual areas of scratches 24 h after the introduction of wounds to the initial areas of scratches. As shown in Figure 6A -B, the unaffected areas were significantly larger for U251 cells with NUSAP1 depleted, indicating that NUSAP1 contributes to glioma migration.
| DISCUSSION
Treatment of gliomas is still a challenge in that, on one hand, populationbased prevention and early screening are beyond the reach of current strategies 21, 22 and, on the other, the brain-locating characteristic of gliomas and the blood-brain barrier (BBB) undermine the efficacy of surgical resection, radiotherapy, and chemotherapy. 23 Identification of oncogenic markers and design of druggable compounds with an enhanced BBB-penetrating property can offer an avenue for treatment of this malignancy. In this study, we investigated NUSAP1 expression in different grades of gliomas and its effects on biologicals behaviors of glioma cells. We found that NUSAP1 expression was increased with the pathological grade of gliomas rising, which indicates a positive association between the NUSAP1 level and the grade of gliomas.
Moreover, NUSAP1 could serve as a prognosis marker for patients' overall survival and a proliferation marker for glioma cells.
Accumulating evidence has shown that low-grade gliomas have the potential to evolve into high-grade gliomas, and this process can be triggered by factors such as inflammation in the tumor microenvironment and somatic mutation. [24] [25] [26] Malignant transformation of low-grade gliomas threatens the prognosis of patients seriously. According to a previous study, the overall survival was not significantly different between patients with secondary GBM (transformed from a lower grade glioma) and those with primary GBM. 27 Our data showed that knockdown of NUSAP1 suppressed proliferation of U251 cells by inducing apoptosis and cell cycle arrest at G2/M phase. In addition, NUSAP1 depletion rendered U251 cells impaired migratory ability. In zebrafish embryos, decreased migration of neural crest cells was also observed when NUSAP1 was depleted. 28 These results imply that targeting NUSAP1 may attenuate malignancy of high-grade gliomas which are characterized by rapid growth and aggressiveness. 29, 30 And, this was supported by the finding that glioma patients with high NUSAP1 expression exhibited significantly reduced overall survival than those with low expression of NUSAP1, according to Kaplan-Meier analysis. Considering that the poorer prognosis of glioma patients was likely due to high tumor grades but not due to high NUSAP1 expression, we performed multivariate
Cox regression analyses and found that NUSAP1 was an independent prognostic factor. However, in vivo experiments are warranted to test effects of NUSAP1 under conditions resembling the physiological environment. In addition, NUSAP1 expression was correlated with retinal neovascularization in mouse models of oxygen-induced retinopathy. 31 As angiogenesis is a rate-limiting step which guarantees sufficient nutrients and oxygen supply in tumor growth, 32, 33 targeting NUSAP1 may hold promise in preventing tumor progression in this respect. However, similar results remain to be replicated in human gliomas.
Distinguishing cancer cells from normal cells and thereby killing
tumors selectively is a desired strategy for oncotherapy. 34 Neural stem cell (NSC)-based therapy is such a tumor-targeting approach owing to the glioma tropism of NSCs. 23, 35 Given that NUSAP1 is prolifera- 
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